Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study

Biegus, J. et al. (2016) Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. European Journal of Heart Failure, 18(7), pp. 830-839. (doi: 10.1002/ejhf.532) (PMID:27170455)

128364.pdf - Accepted Version



Aims: Episodes of acute heart failure (AHF) unfavourably affect multiple organs, which may have an adverse impact on the outcomes. We investigated the prevalence and clinical consequences of abnormal liver function tests (LFTs) in AHF patients enrolled in the PROTECT study. Methods and results: The LFTs comprised serial assessment of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and albumin at baseline and during follow-up (daily until discharge, on days 7 and 14). The prevalence of abnormal LFTs (above upper limit of normal for AST and ALT or below lower limit of normal for albumin) was: at baseline AST 20%, ALT 12%, albumin 40%; and at day 14: AST 15%, ALT 9%, albumin 26%. Abnormal LFTs at baseline were associated with a higher risk of in-hospital death with odds ratios [95% confidence interval (CI)] of 3.5 (1.7–7.3) for AST, 3.9 (1.8–8.4) for ALT, and 2.8 (1.3–5.9) for albumin (all P < 0.01). Abnormal baseline and discharge LFTs had an unfavourable impact on 180-day mortality with hazard ratios (95% CI) for baseline AST, ALT, and albumin of 1.3 (1.0–1.7), 1.1 (1.0–1.2), 1.4 (1.1–1.8), respectively, and 1.5 (1.1–2.0), 1.5 (1.0–2.2), and 1.6 (1.2–2.1), for discharge AST, ALT, albumin, respectively (all P < 0.05). Analysis of LFTs trajectories (calculated as changes in LFTs over time) revealed that increasing AST and ALT on day 3 as well as decreasing albumin on day 4 were independent prognosticators of 180-day outcome (all P < 0.05). Conclusions: Abnormal LFTs are frequent in AHF at baseline and during hospital stay and predict worse outcomes. Whether this association is causal and what are the underlying mechanisms involved require further study.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Cleland, Professor John
Authors: Biegus, J., Hillege, H. L., Postmus, D., Valente, M. A.E., Bloomfield, D. M., Cleland, J. G.F., Cotter, G., Davison, B. A., Dittrich, H. C., Fiuzat, M., Givertz, M. M., Massie, B. M., Metra, M., Teerlink, J. R., Voors, A. A., O'Connor, C. M., and Ponikowski, P.
Subjects:R Medicine > R Medicine (General)
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:European Journal of Heart Failure
ISSN (Online):1879-0844
Published Online:12 May 2016
Copyright Holders:Copyright © 2016 European Society of Cardiology
First Published:First published in European Journal of Heart Failure 18(7): 830-839
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record